4990 results about "Urology" patented technology

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.

This disclosure relates to a method of treating depression and / or reducing risk of suicide, comprising administering a combination of about 90 mg to about 120 mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion, and about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another form of dextromethorphan. The combination may be administered twice a day to a human being suffering from major depressive disorder and having a score of 3 or greater on the Suicidality Item of the Montgomery-Åsberg Depression Rating Scale (MADRS-SI).

The invention relates to the technical field of diagnosis, in particular to a diagnosis and treatment auxiliary system and method for the obstetrics and gynecology department, and the system comprises a parameter collection module, a feature offset recognition module, a feature reconstruction module, a collaborative trend recognition module and a diagnosis and treatment suggestion generation module. According to the system and the method, the body temperature, the heart rate, the pulse, the blood pressure and the image edge density are synchronously acquired and the timestamps are bound, so that a structured diagnosis and treatment data unit is formed, the time sequence comparison capability of multi-source information is effectively improved, and potential risk points can be positioned and feature tags can be constructed based on a numerical value offset identification and synchronous index combined judgment mechanism; according to the method, physical signs, images and laboratory data are normalized and fused into three-dimensional vectors, cross-dimensional feature linkage expression is achieved, the dynamic insight ability to pathological state changes is improved by screening features with large variation amplitude and long duration time and judging trend consistency, and the accurate response to the fetal risk state is enhanced by combining a specific trend combination matching rule.

Disclosed herein is urinary output monitoring system including a urinary collection device having a flow meter in communication with a monitor. The urinary collection device catheter includes a urine collection bag, a drainage tube and a urinary catheter. A console of the flow meter wirelessly communicates with a console of the monitor. The monitor depicts urine flow rate information on a display and wirelessly transmits urine flow rate information to an EMR system. The flow meter includes a flow meter identifier and the system links the urine flow rate information to the flow meter identifier. The monitor further links the flow meter identifier with a patient identification from the EMR system and depicts the patient identification on the display.

The invention provides an early-stage automatic identification method and system for acute kidney injury related to cardiac surgery, and relates to the technical field of physiological parameter detection. The method comprises the following steps: acquiring average arterial pressure, cardiac blood discharge volume, central venous pressure and blood oxygen saturation, regularly recording and extracting data of adjacent time points, calculating a variation range, screening a mutation region, judging whether a reference range is exceeded or not, analyzing a multi-parameter synchronous variation condition, and marking a hemodynamics abnormal state. According to the method, abnormal changes of hemodynamics and urine metabolism are accurately recognized through real-time monitoring and multi-parameter analysis, the urine flow rate and the metabolite excretion rate are combined, misjudgment of a single index is avoided, the fineness of renal function change analysis is improved, the high-risk time period is accurately positioned through time cross comparison, the diagnosis accuracy is improved, and the diagnosis accuracy is improved. Trend analysis and risk grade division enable the change of the illness state to be more visual, and a real-time early warning system effectively monitors the fluctuation trend, optimizes clinical management and improves the timeliness of medical response.

The invention belongs to the technical field of biological medicines, and particularly relates to a composition for treating male erectile dysfunction and application thereof. The oyster polypeptide is prepared by enzymolysis of oyster protein, can effectively promote proliferation of testicular interstitial cells, enhance and improve sexual desire and improve sexual behavior, has certain clinical application value, has the advantages of simple preparation, easy absorption and the like, and is easy to popularize and apply.

The disclosure provides methods of identifying a subject for treatment with an anti-ox-LDL antibody. The disclosure also provides methods of treating a subject with an anti-ox-LDL antibody, wherein the subject has been identified to as a candidate for anti-oxLDL antibody therapy. The methods described herein use computed tomography to identify subjects who are a candidate for anti-oxLDL antibody therapy, wherein a subject may be determined to be a candidate for anti-oxLDL antibody therapy by evaluating their fat attenuation index (FAI), perivascular adipose tissue (PVAT), pericoronary adipose tissue, FAI score, FAI percentile, or CaRi-Heart® Risk score.

The invention discloses an abdominal aortic aneurysm progress prediction method and system based on cross-modal knowledge distillation. The method comprises the following steps: collecting blood of a target object; the method comprises the following steps: detecting the concentration of blood protein fingerprint markers of blood of a target object, wherein the blood protein fingerprint markers comprise matrix metalloproteinase-12, calcitonin-related polypeptide-alpha, uromodulin, nerve injury induction protein-1, glycosylated hemoglobin A1c and fibroblast growth factor-9; carrying out abdominal aortic aneurysm risk calculation by calling Student-net of cross-modal knowledge distillation based on the blood protein fingerprint marker concentration; wherein the input of the Teaser-net of the cross-modal knowledge distillation comprises a CTA image feature and a pathological section feature, and a category probability vector output by the Student-net is aligned with a category probability vector output by the Teaser-net; and outputting the risk level of the abdominal aortic aneurysm and the probability of occurrence / progress / rupture of the abdominal aortic aneurysm in the preset year. And the development of the aortic aneurysm disease is accurately predicted.

The invention belongs to the field of biomedicine, and particularly relates to application of CRYL1 protein in preparation of a product for evaluation, diagnosis or auxiliary diagnosis of postoperative recurrence risk of calcium oxalate kidney stone combined with renal nipple calcium spot, and the sequence of the CRYL1 protein is shown as SEQ ID NO.1. The invention discovers that the expression of the CRYL1 protein in renal tubules and collecting tube cells of renal papillary calcium spot tissues is reduced for the first time, and tests prove that the urine CRYL1 protein is a predictive factor and a predictive marker for postoperative recurrence of a patient with CaOx kidney stone combined with renal papillary calcium spot. The CRYL1 protein detection kit is further researched and developed to be used for detecting or evaluating the postoperative recurrence risk of patients suffering from CaOx kidney stone combined with renal nipple calcium spots, personalized follow-up visit and prevention schemes of the patients are promoted, and the CRYL1 protein detection kit has huge clinical application prospects.

The invention provides a method of reducing the severity of, or treating, thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.

The invention discloses a diabetic nephropathy risk assessment and prediction system based on platelet indexes, and particularly relates to the technical field of disease risk prediction, which comprises a platelet index acquisition module, a drug use data acquisition module, a drug intervention assessment module, an index correction module, a clustering analysis module and a diabetic nephropathy risk assessment module, the method comprises the following steps: acquiring platelet related detection indexes and historical medication data of a patient, calculating a drug intervention influence index and generating a correction factor, realizing platelet index reverse reduction correction by adopting a convolutional neural network model, determining a similar group in combination with clustering analysis, and dynamically evaluating the risk of diabetic nephropathy based on the average morbidity of the group. Personalized accurate prediction is realized; the platelet index correction accuracy is improved, individualized drug intervention elimination is achieved, the similar population clustering analysis precision is enhanced, diabetic nephropathy risk prediction is dynamically adjusted in combination with comprehensive scores, and the early screening and individualized intervention effects are improved.

The invention belongs to the technical field of biological medicines, and particularly relates to application of secretory lactase-like protein (LCTL) as a diagnostic marker in preparation of a diagnostic kit for chronic kidney diseases. According to the present invention, the secretory form of the LCTL is found for the first time, the secretory LCTL content in the human serum is detected by using the existing commercial ELISA kit for the first time, and the further research finds that the secretory LCTL content in the serum of the chronic kidney disease patient is significantly reduced compared with the normal person; and the content of the LCTL in the serum is obviously related to the renal function impairment degree and proteinuria degree of the patient, so that the application of the secretory LCTL in preparing the biomarker for diagnosing the chronic kidney disease is provided for the first time. The invention provides a new method for chronic kidney disease diagnosis, and has important clinical significance and commercial value.

Described herein are methods of treating or reducing the severity of thyroid eye disease (TED), as well as antibodies that bind and inhibit signaling through the insulin-like growth factor receptor 1, useful in the methods.

The invention relates to the field of preparation and application of biological peptides, in particular to a swelling hippocampal peptide and application thereof in preparation of uric acid reducing and gout resisting products. The amino acid sequence is shown as SEQ ID NO.1. The uric acid reducing effect of the compound is proved through in-vitro xanthine oxidase (XOD) and adenosine deaminase (ADA) inhibition experiments and cell experiments; on the basis, the uric acid reducing and gout resisting activity of the peptide sequence is further verified by means of a hyperuricemia animal model. The achievement provides a solid theoretical support for high-value development and utilization of the hippocampus japonicus and research and development of uric acid reducing and gout resisting related products.

Disclosed herein are apparatuses, systems, kits, and methods for treating skin, such as skin tightening or for treating diseases, disorders, and conditions that would benefit from tissue area or volume reduction, skin restoration, skin tightening, skin lifting, and / or skin repositioning and / or for generally improving skin function or appearance (e.g., the removal of unwanted skin features or irregularities such as sebaceous glands, sweat glands, hair follicles, necrosis, and fibrosis). Such apparatuses, systems, kits, and methods comprise an apparatus having a handheld main body and a detachably attachable tip comprising one or more needles.

Systems, devices, and methods are provided that control, support, and / or elongate a cervix to treat pregnancy complications and / or delay an onset of labor so that a gestational period for a fetus may be extended, thereby preventing preterm labor and delivery of the fetus. The cervical control systems may include a main body configured for placement in a vagina. The main body has in internal passageway configured for acceptance of a cervix therein and an inflatable and / or expandable inner cuff extends from portion of the internal passageway. The inner cuff may be expandable inward toward the cervix, or downward away from the uterus, or both inward and downward so that the inner cuff may engage, or grip, the cervix thereby holding the cervical control system in place while compressing the cervix closed, elongating the cervix, and / or adjusting an angle of orientation of the cervix.

The invention provides a kit for detecting spermatogenic ability of azoospermia patients and application thereof, and belongs to the technical field of reproductive medicines.The kit comprises the following reagents: testis tissue digestive juice and testis single cell flow staining fluid; the testis single cell flow type staining solution comprises a DNA (Deoxyribose Nucleic Acid) staining solution Hoechst 33342 and an RNA (Ribonucleic Acid) staining solution # imgabs0 # RNASelectTM green fluorescent cell staining agent; according to the kit, double staining of DNA (deoxyribonucleic acid) and RNA (ribonucleic acid) is carried out on testis single cells, and a fluorescence activated cell sorting technique is matched, so that refining of testis single cell subgroups of azoospermia patients is realized, and the spermatogenic ability of the azoospermia patients is determined according to a testis single cell subgroup subdivision result. The kit disclosed by the invention is used for pre-operation evaluation of a microscopic sperm extraction operation, is used for judging whether a patient has spermatogenic ability and is suitable for microscopic sperm extraction or not, can also be used for guiding the patient to further clarify the cause of disease, and has important clinical significance.

The invention discloses a medical sodium hyaluronate skin repair gel and a preparation method thereof, and mainly relates to the technical field of hyaluronic acid, the medical sodium hyaluronate skin repair gel comprises the following components: sodium hyaluronate, a synergist, glycerol, carbomer, 1, 3-butanediol, triethanolamine and water. Compared with the prior art, the medical sodium hyaluronate skin repair gel prepared by the invention can relieve erythema, pruritus and other symptoms caused by skin inflammation; the wound dressing can also be used for nursing non-chronic wounds, such as superficial wounds, sutured wounds after operations, mechanical wounds and the like; meanwhile, a bacteriostatic environment for wound healing is kept, and skin repair is accelerated; the scar hyperplasia phenomenon in the skin wound repairing process is reduced.

The invention discloses midstream urine collection equipment with high sealing performance, belongs to the technical field of midstream urine collection, and aims to solve the problems that a patient cannot accurately control the urination rhythm, so that the boundary between forepart urine and midstream urine is fuzzy, the collected midstream urine contains part of forepart urine, and the midstream urine collection accuracy is influenced. A fixing frame is fixed to the inner side wall of the collecting hopper, a contact plate is arranged on one side of the fixing frame, four evenly-distributed positioning columns are fixed to the side, close to the fixing frame, of the contact plate, and the positioning columns are movably connected to one side face of the fixing frame; after the contact plate is impacted by urine, impact force can be transmitted to the pressure sensor, the impact force of the urine can be detected through the arranged pressure sensor, and then the pressure sensor is matched with the PLC to distinguish anterior urine, midstream urine and posterior urine, so that the boundary distinguishing between the midstream urine and the anterior urine is obvious, and the accuracy of urine detection is improved. The problem that the accuracy of midstream urine collection is affected due to the fact that the collected midstream urine contains part of anterior urine due to autonomous judgment of a patient is avoided.

The invention discloses a renal artery balloon catheter for local drug perfusion, and relates to the technical field of renal artery balloon catheters, the renal artery balloon catheter comprises an access unit, and the access unit comprises a connecting end, a perfusion joint arranged at one end of the connecting end, and a liquid injection joint arranged on the outer wall of the connecting end. The balloon has the advantages that a traditional integrally-injection-molded balloon is changed to be composed of multiple independent tubes, the balloon can be matched with the renal artery with the larger bending degree, the production cost of an enterprise can be reduced, the corrugated balloon formed through expansion and the concave-convex surface can disperse contact pressure, local compression on the intima is reduced, and the balloon has the good sealing effect. And the'grooves' of the waveform structure are in multi-point contact with the blood vessel wall, so that the friction force is increased, and the balloon is prevented from sliding under the impact of blood flow.

The invention relates to the technical field of RT type lacrimal passage drainage tube application, and particularly discloses an RT tube application method for simultaneously solving upper and lower lacrimal passage blockage, which comprises the following steps of: firstly, performing preoperative local anesthesia on a patient; the upper lacrimal punctum and the lower lacrimal punctum of the diseased eye are expanded, and after a thin probe is used for probing the obstruction position of the lacrimal passage from the upper lacrimal ductule and the lower lacrimal ductule, the lacrimal passage is flushed Expanding the obstructed part of the lacrimal passage by using a large probe; then, the artificial lacrimal duct is implanted, the RT tube is implanted into the upper and lower lacrimal ducts at the same time, the problem of blockage of multiple parts is solved through a single instrument, repeated damage to periorbital tissue caused by fractional operations is avoided, and the device is particularly suitable for complex cases that upper and lower lacrimal canalicules and nasolacrimal ducts are blocked or narrow at the same time; the whole-course drainage of the tears from the upper and lower lacrimal passages to the nasal cavity is further ensured, and the physiological path of tear circulation is recovered; the RT tube is placed, skin or mucous membrane does not need to be cut open, no scar is visible after operation, and the requirement for periocular beauty is met.

The invention discloses homocysteine as a Graves eye disease biomarker and application thereof, the biomarker is homocysteine (Hcy), application of a reagent for detecting the biomarker in preparation of a product for diagnosing Graves eye diseases, and the reagent is used for detecting the level of Hcy in sample serum. By detecting the level of homocysteine (Hcy) in serum, an objective and quantitative biomarker is provided for diagnosis of Graves eye diseases (GO), the diagnosis accuracy is remarkably improved, and the defects that existing clinical activity scores are high in subjectivity and insensitive to latent patients are overcome; the Hcy level is in positive correlation with GO activity, and can be used for monitoring disease progression and treatment effect, optimizing disease management, reducing serious complications and improving life quality of patients.

A nasal dispensing device and pharmaceutical composition includes a container; a dispenser head having at least a pump, a dispensing channel, and a dispensing orifice; a dip tube; and a pharmaceutical composition comprising mometasone, an ester thereof (e.g., mometasone furoate), or a salt thereof and olopatadine or its salt (e.g., olopatadine hydrochloride). The container can have a conically shaped internal bottom, angled downwardly toward a center, and a further angularly deepened well, centrally located, with the dip tube extending into the well. An optional cap is provided that includes a sealing sleeve communicating in a seal tight manner with a perimeter of a lateral wall of the dispenser head.

The invention relates to application of 1, 2, 3, 4, 6-O-pentagalloylglucose in preparation of a medicine for resisting cholestatic liver diseases, and belongs to the technical field of medicinal chemistry. The 1, 2, 3, 4, 6-O-pentagalloylglucose provided by the invention can be used for promoting bile acid excretion by reducing WDR6 protein expression. In-vivo and in-vitro experiments prove that the 1, 2, 3, 4, 6-O-pentagalloylglucose can be used for remarkably relieving the symptom of the cholestatic liver disease. In addition, the 1, 2, 3, 4, 6-O-pentagalloylglucose has no obvious toxic or side effect, and has no obvious influence on the liver function and the kidney function. The 1, 2, 3, 4, 6-O-pentagalloylglucose has a wide anti-cholestatic liver disease spectrum, and is suitable for various cholestatic liver diseases, such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and the like.

The invention provides a diabetic nephropathy early warning method, system, equipment and medium, and relates to the technical field of medical data analysis and prediction.The method comprises the steps that multiple urine samples of a user are collected, target urine protein detection is conducted, and multiple urine protein concentrations are obtained; each urine protein concentration is combined with a normal urine protein concentration set to be input into an abnormal data recognition tree, the number of layers of multiple recognition nodes is obtained, and the detection confidence coefficient is obtained through calculation; configuring an abnormal proportion according to the detection confidence coefficient, inputting a plurality of urine protein concentration combination normal urine protein concentration sets into an abnormal data identification tree, deleting urine protein concentrations divided into abnormal data in the abnormal proportion before, and obtaining screened urine protein concentrations; according to the screened urine protein concentration, an auxiliary early warning coefficient is obtained through calculation, and early warning is carried out. The technical problem of low early warning accuracy of diabetic nephropathy in the prior art is solved.

The invention relates to the technical field of biology, in particular to a swelling hippocampal peptide as well as a preparation method and application thereof. Comprising a polypeptide with an amino acid sequence as shown in SEQ ID NO.1. The hippocampus antioxidative peptide is prepared by adopting an ultrahigh pressure pretreatment and enzymolysis technology, the adopted extraction process is simple in route, and the time and the production cost are effectively saved; an animal model is utilized to prove the antioxidation effect and the effect of improving male reproductive disorder and testis injury of the hippocampal swelling peptide; and on the basis, a novel peptide fragment with high activity, no toxicity and no sensitization is obtained.

The invention provides cubilose peptide and a key preparation method of cubilose peptide maternity cubilose, and the preparation method of the cubilose peptide comprises the following steps: soaking dry cubilose in pure water at 0-4 DEG C according to a material-liquid ratio of 1: 10 for 2 hours, scattering, and spin-drying to obtain soaked cubilose; mixing the soaked cubilose with pure water according to a mass ratio of 1: (15-20), sealing, stewing at 121-123 DEG C for 12-15 minutes, cooling to room temperature, and repeatedly stewing once to obtain fresh stewed cubilose; carrying out an in-vitro digestion experiment on the freshly stewed cubilose, and simulating the digestion process of the freshly stewed cubilose in gastrointestinal tracts to obtain digested cubilose; and centrifuging the digested cubilose to obtain a supernatant, treating the supernatant, carrying out protein sequencing, and carrying out on-line database comparison to screen out peptide fragments with high matching degree and response value greater than 109, thereby obtaining the cubilose peptide. The cubilose peptide can significantly improve the proliferation rate of nerve cells, and provides a cell basis for the development of a nervous system.

Disclosed here are kits comprising pre-packed stabilizing solutions for stabilizing combinations of biomarkers demonstrating sufficient accuracy and specificity for identifying kidney injuries. Such kits can be better adapted for sample collection at a subject's dwelling, thus easing the burdensome requirement of continuous monitoring for kidney injury.

The invention relates to the technical field of computer medical detection, in particular to a thyroid nodule benign and malignant classification method based on clinical information, radiomics and gene detection. According to the method, pathological diagnosis of thyroid nodules is used as a dependent variable, detection data including radiomics characteristics and molecular omics are used as continuous variables, and the detection data of at least three genes CLDN10, HMGA2 and LANM3 are selected as the data of the molecular omics; meanwhile, in combination with part of clinical pathological characteristics including gender, age and BRAF V600E mutation condition factors, a thyroid nodule preoperative diagnosis prediction model based on radiomics and molecular omics is constructed through an SVM modeling method. Gene detection, radiomics and clinical basic information are combined, and a thyroid nodule diagnosis model based on the combination is established on the basis of Chinese population. The method is used for assisting clinicians in distinguishing benign and malignant thyroid nodules and guiding clinical decisions